60 Degrees Pharmaceuticals, Inc. · NASDAQ:SXTP

60 Degrees Pharmaceuticals — Investor Presentation (January 2026)

26 slides from 60 Degrees Pharmaceuticals's investor presentation, Jan 8, 2026

1. Slide 1: Webinar, January 8, 2026

   ©2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. October 2025 1 - 8 - 26 Webinar

2. Slide 2: Disclaimer and Forward-looking Statements

   Disclaimer and Forward - looking Statements ©2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. DISCLAIMER. The information contained herein has been prepared to assist prospective investors in making their own evaluation of 60 Degrees Pharmaceuticals, Inc. (the “Company”) and d

3. Slide 3: Market Cap: $2.1 million

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Market Cap: $2.1 million

4. Slide 4: Use of ARAKODA for Chronic Babesiosis Is Increasing Sales

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 0 20000 40000 60000 80000 100000 120000 140000 160000 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 9/2019 8/2025 PANDEMIC SUPPLY CHAIN DISRUPTION PATIENT BABESIOSIS CALL

5. Slide 5: Gross Margins Look Good, So Our Focus is on Increasing Sales

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Gross Margins Look Good, So Our Focus is on Increasing Sales Net Revenue and Gross Margin in thousands Notes: 1. Q2 2025 Pharmacy Deliveries down due to temporary stock out. 2. Q3 2025 Net Loss due to anticipated expiring inven

6. Slide 6: Future Sales of Arakoda Could Increase by Orders of Magnitude

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 0 50 100 150 200 250 Annualized Sales Now Max Potential Sales (2035) Future Sales of Arakoda Could Increase by Orders of Magnitude* *Assuming company market research is accurate and FDA approval of Arakoda is achieved

7. Slide 7: Future Arakoda Sales for Chronic Babesiosis Could be Higher Than Malaria

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Malaria Prevention Chronic Babesiosis Other Babesiosis Future Arakoda Sales for Chronic Babesiosis Could be Higher Than Malaria* *Based on internal market research that assumes FDA approval Arakoda for treatment of babesiosis

8. Slide 8: Patient testimonial on malaria

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Roberts wrote, “Malaria is an awful disease that needs to be attacked full - force when a diagnosis is made. In my time here, I’ve gone from being so sick that any dog would take pity on me to being ready to fire up the grill o

9. Slide 9: Malaria in Travelers is Increasing Because They Don't Take Their Meds

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Malaria in Travelers is Increasing Because They Don’t Take Their Meds No vaccines 95% of cases in people who don’t take their meds • References: 1. Mace KE, et al. MMWR Surveill Summ . 2022;71(8):1 - 35. 2. Centers for Disease

10. Slide 10: Selecting The Correct Antimalarial Prophylaxis is Complicated!

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Selecting The Correct Antimalarial Prophylaxis is Complicated! P. vivax (relapses post travel) P. falciparum (deadly but does not relapse) Very little P. vivax malaria in Africa From MAP Project

11. Slide 11: ARAKODA Has a Lower Pill Burden

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. ARAKODA Has a Lower Pill Burden* Standard of care Atovaquone/proguanil/primaquine 53 pills ARAKODA 16 pills *For one month trip

12. Slide 12: Arakoda Market Research Revealed Some Challenges to Solve

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. A rakoda Market Research Revealed Some Challenges to Solve Brand recognition is low HCPs and patients liked product profile Generic alternatives have lower out of pocket costs G6PD testing requirement a potential barrier for so

13. Slide 13: Commercial Pilot for Malaria Indication Addresses Barriers to Use

    Commercial Pilot for Malaria Indication Addresses Barriers to Use Increase Awareness and Differentiate ARAKODA D ifferentiate ARAKODA from the generic competition with a clear and compelling value story through different channels Drive ARAKODA Trial & Usage Additional Inside Sales Representatives -

14. Slide 14: Babesiosis is a Parasite Transmitted By Ticks and Blood Donation

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Babesiosis is a Parasite Transmitted By Ticks and Blood Donation • Reference: 1. Centers for Disease Control. Babesiosis. 2017. www.cdc.gov/dpdx/babesiosis/index.html

15. Slide 15: Blood Donation Screening Decreases Babesia Transmission

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Blood Donation Screening Decreases Babesia Transmission, Revealing Hidden Resevoir of Viable Parasites Observation: Blood donors usually do not donate blood if they are feeling sick and would likely not know they had a Babesia

16. Slide 16: Conventional Treatments Resolve Symptoms, But Unclear if Parasite Reservoirs Eliminated

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Lower Limit of Analytical Sensitivity (parasites/mL) Target Diagnostic Method(s) 100,000 Whole organisms Microscopy 1,540 18s RNA probe (DNA) Real Time PCR (e.g. Mayo) 3 RNA Blood Bank Test (transcription amplified) Observation

17. Slide 17: Clinical Significance of Residual Parasite Burden: Main-Stream Perspective

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Clinical Significance of Residual Parasite Burden: Main - Stream Perspective Immunocompetent person Immunosuppressed person Infection clears Infection clears, but becomes sick again Person with no spleen

18. Slide 18: Clinical Significance of Persistent Infection in Dysregulated Immune Systems

    ©2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Clinical Significance of Persistent Infection in Individuals With Dysregulated Immune Systems Has Not Been Studied Gets COVID Long Covid Dysregulated Immune system Infected with Babesia ?

19. Slide 19: Chronic Babesiosis is a Problem: Prescribing Physician Perspective

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Chronic Babesiosis is a Problem: Prescribing Physician Perspective Dr. Richard Horowitz: “Chronic Babesiosis is seen in the vast majority of my chronically ill patients with Lyme disease. Present regimens with Mepron and Zithro

20. Slide 20: Tafenoquine Kills Babesia and Malaria Parasites the Same Way

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Tafenoquine Kills Babesia and Malaria Parasites the Same Way, at Similar Doses Tafenoquine kills Babesia and Malaria parasites in the same way Similar doses clear both infections in animal models Giemsa - stained blood smears o

21. Slide 21: Tafenoquine Had an 80% Cure Rate in 5 Immunosuppressed Patients

    ©2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Tafenoquine Had an 80% Cure Rate in 5 Immunosuppressed Babesiosis Patients With Weekly Dosing Plus Standard of Care 1 Representative Case 1. Krause PJ, et al. Clin Infect Dis. doi:10.1093/ cid /ciae238

22. Slide 22: Research Strategy Focused on FDA Approval and Broadening Acceptance

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Demonstrate clinical improvement over standard of care and no new safety signal Research Strategy Focused on FDA Approval and Broadening Acceptance Tidy up Prove that chronic babesiosis can be diagnostically confirmed Apply for

23. Slide 23: Three Clinical Trials of Arakoda Will Confirm Efficacy Against Babesiosis

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Three Clinical Trials of Arakoda Will Confirm Efficacy Against Babesiosis and That Chronic Babesiosis Is Associated With Persistent Infection* Initial Enrolment Complete^ Number Enrolled Min/Max Sample Size Type Population Comb

24. Slide 24: reserved.

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.

25. Slide 25: NCT06656351 May Prove Chronic Babesiosis is Due to Persistent Infection

    ©2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. NCT96656351 May Prove Chronic Babesiosis is Due to Persistent Infection* A Phase II Open Label Study of Tafenoquine in Chronic Babesiosis Patients Patients (key inclusions) Severe disabling fatigue with substantial functional i

26. Slide 26: Achieving Key Milestones Will Derisk Business Plan in 2026

    Achieving Key Milestones Will Derisk Business Plan in 2026 Q 1/2 202 6 Q 1/2 202 6 Q 3 202 6 Q 3 202 6 Q 4 202 6 Q4 2026 Diagnostic Confirmation of Chronic Babesiosis Additional Sales Outputs From ARAKODA Commercial Program Additional Cures in Expanded Access Study Minimum Enrolment for Interim Anal

60 Degrees Pharmaceuticals — Investor Presentation (January 2026) on 6ix